CBD research on - Pain
Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis.
These results demonstrate that TRPV1 receptor could be a molecular target of the CBD antihyperalgesic action.
The results indicate a potential for therapeutic use of cannabidiol in chronic painful states.
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
Pain relief associated with both THC and CBD was significantly superior to placebo. Impaired bladder control, muscle spasms and spasticity were improved by cannabis in some patients.